ABK Patent Attorneys

The present invention relates to brain implant for linear release of 5-aminolevulinic acid comprising:a) a core comprising:5-aminolevulinic acid and a core polymer,wherein the core polymer is selected from the group consisting of poly(lactic acid) (PLA), poly(ethylene oxide) (PEO), poly(ethylene glycol) (PEG), and poly(lactic-co-glycolic acid) (PLGA);andb) a shell consisting of an upper membrane, a spacer, and a lower membrane, wherein the upper membrane, the spacer, and the lower membrane each comprise a shell polymer, wherein the shell polymer is poly(lactic acid) (PLA);characterized in thatthe shell polymer is in a range from 20 wt.% to 60 wt.% based on the total weight of the brain implant;andwhen the core polymer is poly(lactic acid) (PLA), poly(ethylene oxide) (PEO), poly(ethylene glycol) (PEG), the core contains 5-aminolevulinic acid in a range from 25 wt.% to 45 wt.%, and the core polymer in a range from 75 wt.% to 55 wt.% based on the total weight of the core;orwhen the core polymer is poly(lactic-co-glycolic acid) (PLGA), the core contains 5-aminolevulinic acid in a range from 65 wt.% to 75 wt.% and the core polymer in a range from 35 wt.% to 25 wt.% based on the total weight of the core;a preparation method of said brain implant,anda medical use thereof, in particular in the prophylaxis and/or treatment of brain cancer.

The present invention relates to composition for use in treating brain tumor in a subject, the composition comprising 5-aminolevulinic acid, wherein, in use, the composition is provided in an direct intracranial drug delivery system to a subject after at least partial surgical resection of the brain tumor, and wherein the direct intracranial drug delivery system releases a therapeutically effective amount of the composition into a resection cavity in a controlled-release manner. Said composition is particularly useful in treating glioblastoma in combination with artemisinin compounds and optionally anti-glioblastoma drugs. Said composition is particularly useful in combination with radiotherapy and/or photodynamic therapy.

The present invention relates to novel pyrazolo[5,1-c][1,4]benzoxazepine derivatives of general formula (I) and stereoisomeric forms, hydrates, solvates and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing at least one pyrazolo[5,1-c][1,4]benzoxazepine derivative together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said pyrazolo[5,1-c][1,4]benzoxazepine derivatives are particularly useful for the treatment and/or prophylaxis of proliferative diseases, immunological disorders, infectious diseases, autoimmune diseases, inflammatory disorders and circulatory diseases.

The present invention relates to an ultrasound imaging system (100) comprising a robotic arm (3), an ultrasound probe (5), at least one depth camera (6) for capturing a depth image of a patient's body (1) and a surrounding, an ultrasound probe pose determination unit (10); a dense pose determination unit (20), and an ultrasound probe pose transformation unit (30), wherein the ultrasound probe position determination unit (10) is configured to determine a six-dimensional pose of the ultrasound probe (5), wherein ultrasound probe pose transformation unit (30) is configured to transform the six-dimensional pose of the ultrasound probe (5) in the depth image to the 3D human body surface model and vice versa using an invertible coordinate transformation function f (pd,probe) = pm,probe obtained by estimating dense correspondences between a selected target region in the depth image of the patient's body and a 3D human body surface model. Said ultrasound imaging system (100) therefore allows recording a position of an ultrasound probe (5) relative to a patient's body (1) autonomous positioning of an ultrasound probe (5) on a patient's body (1) independent of the body position. A further aspect of the present invention is related to a method for recording a six-dimensional pose and/or trajectory of an ultrasound probe (5) relative to a patient's body. A further aspect of the present invention is related to a method for autonomous positioning of an ultrasound probe (5) on a patient's body (1).

The present invention relates to self-assembling peptides consisting of at least 6 amino acids and containing the amino acid sequence X1-A4-A5-A6-X2. Said peptides self-assemble into fibrils especially under physiological conditions in an aqueous dispersion phase thereby forming a hydrogel and are thus particularly useful for forming a hydrogel composition.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …